{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:04:27Z","timestamp":1792253067085,"version":"4.4.0"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T00:00:00Z","timestamp":1363305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sorafenib is a small molecular inhibitor of several tyrosine protein kinases, including vascular endothelial growth factor receptor, platelet\u2010derived growth factor receptor and rapidly accelerated fibrosarcoma kinases, targeting signal transduction and angiogenic pathways. It is approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. The objectives of this prospective phase II trial were to assess the activity and tolerability of sorafenib in patients with recurrent or refractory myeloma. In total, 11 patients were enrolled. Patients received 2\u2009\u00d7\u2009200\u2009mg of sorafenib orally twice daily until completing 13 full cycles or disease progression. Of the side effects, 8.8% grade 3 and 1.1% grade 4 occurred. Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24.4\u2009months and 6.9\u2009month, respectively. Further clinical investigations are recommended to investigate sorafenib single agent activity in myeloma subgroups with ras\u2010\/BRAF\u2010\/vascular endothelial growth factor receptor pathway activation and combination therapy approaches. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2043","type":"journal-article","created":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T16:52:02Z","timestamp":1363366322000},"page":"197-200","source":"Crossref","is-referenced-by-count":31,"title":["Sorafenib in patients with refractory or recurrent multiple myeloma"],"prefix":"10.1002","volume":"31","author":[{"given":"Anna","family":"Yordanova","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, Center for Integrated Oncology (CIO) University of Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Department of Medicine V University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Neben","sequence":"additional","affiliation":[{"name":"Department of Medicine V University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Witzens\u2010Harig","sequence":"additional","affiliation":[{"name":"Department of Medicine V University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"G\u00fctgemann","sequence":"additional","affiliation":[{"name":"Institute of Pathology University of Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc\u2010Steffen","family":"Raab","sequence":"additional","affiliation":[{"name":"Department of Medicine V University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Moehler","sequence":"additional","affiliation":[{"name":"Department of Medicine V University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Department of Medicine V University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo GH","family":"Schmidt\u2010Wolf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Center for Integrated Oncology (CIO) University of Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2876"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184226"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-178350"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1745"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-013458"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.257"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09837"},{"key":"e_1_2_8_10_1","first-page":"1190","article-title":"BAY 43\u20109006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"29","author":"Wilhelm SM","year":"2010","journal-title":"Oncogene"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.142"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.1177"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704555"},{"key":"e_1_2_8_14_1","first-page":"1033","article-title":"Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma","volume":"91","author":"Kimlinger T","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.403"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_8_17_1","first-page":"300","article-title":"Staging and kinetics of multiple myeloma","volume":"13","author":"Durie BG","year":"1986","journal-title":"Semin Oncol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq651"},{"key":"e_1_2_8_21_1","unstructured":"National Cancer Institute.Common terminology criteria for adverse events v3.0 in edition.2003. Available at:http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0143"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.03.006"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.362"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1226-z"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70383-3"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1276-2"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2043","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:03:13Z","timestamp":1700629393000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,15]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1002\/hon.2043"],"URL":"https:\/\/doi.org\/10.1002\/hon.2043","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,15]]}}}